New Medscape article on Cholangiocarcinoma treatment

[Guest guest]

http://www.medscape.com/viewarticle/577978?src=mp & spon=17 & uac=42076ET - also, see

http://www.cancer.gov/clinicaltrials/results/sorafenib-liver0607#top

Sorafenib Increases Survival in Advanced Liver Cancer CME

News Author: Roxanne

CME Author: Désirée Lie, MD, MSEd Sorafenib Increases Survival in Advanced Liver Cancer

July 24, 2008 — Treatment with sorafenib (Nexavar; Onyx/Bayer) can improve the overall survival of patients with advanced hepatocellular carcinoma. Compared with patients who received placebo, sorafenib increased median survival by nearly 3 months, according to a study published in the July 24 issue of the New England Journal of Medicine.

The median overall survival was 10.7 months for patients treated with sorafenib vs 7.9 months for those receiving placebo. The results of the study were initially presented at the 2007 annual meeting of the American Society of Clinical Oncology and reported by Medscape Oncology at that time.

Arne

57 - UC 1977 - PSC 2000

Alive and well in Minnesota